Holen Sie sich die Stockscreener-App
11.91
0.68%
0.08
Handel nachbörslich:
11.90
-0.010
-0.08%
Schlusskurs vom Vortag:
$11.83
Offen:
$11.83
24-Stunden-Volumen:
2.36M
Relative Volume:
0.44
Marktkapitalisierung:
$1.67B
Einnahmen:
$67.67M
Nettoeinkommen (Verlust:
$-412.69M
KGV:
-3.1124
EPS:
-3.8266
Netto-Cashflow:
$-395.87M
1W Leistung:
-0.25%
1M Leistung:
-10.45%
6M Leistung:
+0.34%
1J Leistung:
+9.27%
1-Tages-Spanne:
$11.41
$12.04
1-Wochen-Bereich:
$11.41
$12.31
52-Wochen-Spanne:
$7.95
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.91 | 1.69B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
NTLA|Intellia Therapeutics Inc|Price:11.910|Chg%:+0.080 - TradingKey
NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
Intellia (NTLA) Q2 2026 Earnings Call Transcript - The Globe and Mail
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Wasatch Advisors LP Sells 134,215 Shares of Intellia Therapeutics, Inc. $NTLA - marketbeat.com
Intellia Therapeutics Stock Short Interest Falls to 39.57% - Quiver Quantitative
Intellia Therapeutics, Inc. $NTLA Shares Acquired by Royal Bank of Canada - marketbeat.com
(NTLA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Research Analysts Offer Predictions for NTLA FY2026 Earnings - marketbeat.com
Intellia Therapeutics Insider Buyers See Boost After Market Cap Rose US$168m - Moomoo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
Equities Analysts Issue Forecasts for NTLA Q2 Earnings - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Issues Earnings Results - MarketBeat
Bank of America Securities Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Wall Street Zen - marketbeat.com
Intellia Therapeutics (NTLA) Stock Rises As Pipeline Progress Lifts Sentiment - Sahm
NTLA SWOT Analysis: Financial Resilience Amidst Clinical Advancements Revealed in 10-Q Filing - GuruFocus
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
Intellia Therapeutics Inc earnings matched, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues - Yahoo Finance
State Street (NTLA) stake: 9.23M Intellia Therapeutics shares in 13G filing - Stock Titan
Intellia upgraded at Evercore ISI on nex-z hypothesis (NTLA:NASDAQ) - Seeking Alpha
Intellia Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit - Yahoo Finance
Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring Potential 127.65% Upside with CRISPR Innovations - DirectorsTalk Interviews
Will Intellia’s (NTLA) Narrowing Losses and Heavy R&D Spend Shift Its Risk Reward Narrative? - Yahoo Finance
Intellia Therapeutics Q2 Earnings Call Highlights - marketbeat.com
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... By GuruFocus - Investing.com Canada
Intellia Therapeutics, Inc. Stock 12‑Month Price Target Cut to $25.56, Implies 133% Upside - TradingView
Intellia Therapeutics 2Q 2026: Revenue $7.7M, Net loss $106.6M, EPS $(0.80) — 10-Q Summary - TradingView
[10-Q] Intellia Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Intellia Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlig - GuruFocus
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... - Yahoo Finance
Form 8K Intellia Therapeutics Inc For: 6 August By Investing.com - Investing.com South Africa
Earnings call transcript: Intellia posts Q2 2026 revenue miss as shares slip premarket - Investing.com
Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating - marketscreener.com
Intellia Therapeutics Inc earnings matched, revenue fell short of estimates - Investing.com
INTELLIA THERAPEUTICS, INC. reports results for the quarter ended June 30Earnings Summary - TradingView
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Intellia Therapeutics reports Q2 2026 net loss of $106.6M, $628.4M cash; positive Phase 3 data for lonvo-z - TradingView
Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q2 Revenue $7.7M, Vs. FactSet Est of $13.0M - Moomoo
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Intellia Therapeutics
Intellia Therapeutics Q2 Operating Expenses U - moomoo.com
Intellia plans first-half 2027 U.S. launch if FDA approves hereditary angioedema treatment - Stock Titan
Dimensional Fund Advisors LP Increases Position in Intellia Therapeutics, Inc. $NTLA - marketbeat.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Arrowstreet Capital Limited Partnership Makes New Investment in Intellia Therapeutics, Inc. $NTLA - marketbeat.com
Intellia Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 6 - moomoo.com
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):